Your browser doesn't support javascript.
loading
Structure-function relationship of new peptides activating human Nav1.1.
Lopez, Ludivine; De Waard, Stephan; Meudal, Hervé; Caumes, Cécile; Khakh, Kuldip; Peigneur, Steve; Oliveira-Mendes, Barbara; Lin, Sophia; De Waele, Jolien; Montnach, Jérôme; Cestèle, Sandrine; Tessier, Agnès; Johnson, J P; Mantegazza, Massimo; Tytgat, Jan; Cohen, Charles; Béroud, Rémy; Bosmans, Frank; Landon, Céline; De Waard, Michel.
Affiliation
  • Lopez L; Nantes Université, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France; Smartox Biotechnology, Saint-Egrève, France.
  • De Waard S; Nantes Université, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France; LabEx "Ion Channels, Science and Therapeutics", Valbonne, France.
  • Meudal H; Center for Molecular Biophysics, CNRS, rue Charles Sadron, CS 80054, Orléans 45071, France.
  • Caumes C; Smartox Biotechnology, Saint-Egrève, France.
  • Khakh K; Xenon Pharmaceuticals, Burnaby, British Columbia, Canada.
  • Peigneur S; University of Leuven, 3000 Leuven, Belgium.
  • Oliveira-Mendes B; Nantes Université, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France.
  • Lin S; Xenon Pharmaceuticals, Burnaby, British Columbia, Canada.
  • De Waele J; Department of Basic and Applied Medical Sciences, Ghent University, Ghent, Belgium.
  • Montnach J; Nantes Université, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France.
  • Cestèle S; Université Cote d'Azur, CNRS UMR 7275, Institute of Molecular and Cellular Pharmacology, Valbonne-Sophia Antipolis, France.
  • Tessier A; Nantes Université, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France.
  • Johnson JP; Xenon Pharmaceuticals, Burnaby, British Columbia, Canada.
  • Mantegazza M; Université Cote d'Azur, CNRS UMR 7275, Institute of Molecular and Cellular Pharmacology, Valbonne-Sophia Antipolis, France.
  • Tytgat J; University of Leuven, 3000 Leuven, Belgium.
  • Cohen C; Xenon Pharmaceuticals, Burnaby, British Columbia, Canada.
  • Béroud R; Smartox Biotechnology, Saint-Egrève, France.
  • Bosmans F; Department of Basic and Applied Medical Sciences, Ghent University, Ghent, Belgium.
  • Landon C; Center for Molecular Biophysics, CNRS, rue Charles Sadron, CS 80054, Orléans 45071, France.
  • De Waard M; Nantes Université, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France; Smartox Biotechnology, Saint-Egrève, France; LabEx "Ion Channels, Science and Therapeutics", Valbonne, France. Electronic address: michel.dewaard@univ-nantes.fr.
Biomed Pharmacother ; 165: 115173, 2023 Sep.
Article in En | MEDLINE | ID: mdl-37453200
ABSTRACT
Nav1.1 is an important pharmacological target as this voltage-gated sodium channel is involved in neurological and cardiac syndromes. Channel activators are actively sought to try to compensate for haploinsufficiency in several of these pathologies. Herein we used a natural source of new peptide compounds active on ion channels and screened for drugs capable to inhibit channel inactivation as a way to compensate for decreased channel function. We discovered that JzTx-34 is highly active on Nav1.1 and subsequently performed a full structure-activity relationship investigation to identify its pharmacophore. These experiments will help interpret the mechanism of action of this and formerly identified peptides as well as the future identification of new peptides. We also reveal structural determinants that make natural ICK peptides active against Nav1.1 challenging to synthesize. Altogether, the knowledge gained by this study will help facilitate the discovery and development of new compounds active on this critical ion channel target.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Peptides / Voltage-Gated Sodium Channels Limits: Humans Language: En Year: 2023 Type: Article

Full text: 1 Database: MEDLINE Main subject: Peptides / Voltage-Gated Sodium Channels Limits: Humans Language: En Year: 2023 Type: Article